The IV Therapy Academy

A large Phase 3 trial has added weight to the case for retatrutide as a possible future treatment for adults living with both obesity and type 2 diabetes. The study, published in The Lancet on 29 September 2026, reported substantial average weight loss over 80 weeks in people receiving weekly retatrutide injections. Blood glucose control also improved, which matters because weight and glucose management are closely linked in type 2 diabetes care. The results are promising, bu